Brief: Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal
11/02/2026 10:09
Feb 11 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK: EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL FOR SEVERAL SIRNA ASSETS TO RECEIVE $60 MILLION UPFRONT PAYMENT, UP TO $4.4 BILLION TOTAL LICENSING DEAL FOR 6 PRE-CLINICAL SIRNA PROGRAMS FOR TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS Further company coverage: 6938.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)